ACAD Financial Facts
Net loss: -71.61MCollaborative revenues: 5.27M
See Full Income Statement
See Full Balance Sheet
ACADIA Pharmaceuticals (ACAD) Earnings
|
Expand Research on ACAD
| Next EPS Date | 8/11/26 | EPS Growth Rate | -62.5% |
|---|---|---|---|
| Average EPS % Beat Rate | +299.3% | Revenue Growth Rate | +12.1% |
| Average % Move 1-Wk after EPS | +2.3% | Normal Earnings Time | After Close |
| Date | Qtr | EPS | Cons. | Surprise | Revs | Cons. | Gd. | 1-Week % | 1-Day % | Details | |
|---|---|---|---|---|---|---|---|---|---|---|---|
8/11/26  |
Q226 | N/A | $0.06 | N/A | N/A | $296.63M | = | N/A | N/A | ||
| 5/6/26 | Q126 | $0.02 | $0.05 | -$0.03 | $268.06M | $280.92M | = |  | | Details | |
| 2/25/26 | Q425 | $1.60 | $0.14 | +$1.46 | $284M | $293.78M | = | | | Details | |
| 11/5/25 | Q325 | $0.42 | $0.14 | +$0.28 | $278.6M | $277.08M | = | | | Details | |
| 8/6/25 | Q225 | $0.16 | $0.14 | +$0.02 | $264.6M | $262.44M | = | | | Details | |
| 5/7/25 | Q125 | $0.11 | -$0.02 | +$0.13 | $244.32M | $239.55M | = | | | Details | |
| 2/26/25 | Q424 | $0.86 | $0.22 | +$0.64 | $259.6M | $271.64M | = | | | Details | |
| 11/6/24 | Q324 | $0.20 | $0.14 | +$0.06 | $250.4M | $248.6M | = | | | Details |
